Culture-expanded, bone marrow-derived mesenchymal stem cells can regenerate a critical-sized segmental bone defect
Culture-expanded, bone marrow-derived mesenchymal stem cells can regenerate a critical-sized segmental bone defect
复制标题
DOI：
10.1089/ten.1997.3.173
复制
发表时间：
1997-06-01
影响因子：
--
通讯作者：
Bruder, SP
中科院分区：
文献类型：
--
作者：
Kadiyala, S;Jaiswal, N;Bruder, SP
骨髓已被证明含有能够分化成形成骨、软骨和其他结缔组织的细胞的稀有细胞群。这些细胞被称为间充质干细胞（MSC），可以从骨髓中纯化和培养扩增，并且当异位植入适当的载体中时能够形成骨。为了测试MSC愈合临界尺寸节段性缺损的能力，将同系培养扩增的MSC加载到羟基磷灰石/磷酸三钙（HA/TCP）的多孔圆柱体上，并植入成年大鼠股骨中的8 mm节段性缺损中。为了进行比较，其他缺损接受骨髓加载或无细胞HA/TCP圆柱体，或没有植入物。通过放射学、组织学和定量组织形态计量学在4周和8周评价愈合反应。未接受植入物、无细胞HA/TCP圆柱体或装载新鲜骨髓的圆柱体的缺损在8周内未能愈合。相比之下，接受MSC负载圆柱体的缺损在4周时显示出显著更多的骨形成，并且在8周时完全愈合，宿主-种植体界面愈合良好。组织形态计量学表明，MSC负载的种植体中的骨填充（43%）大于（p < 0.05）骨髓负载的种植体（19%）或无细胞种植体（10%）。
Bone marrow has been shown to contain a population of rare cells capable of differentiating into the cells that form bone, cartilage, and other connective tissues. These cells, referred to as mesenchymal stem cells (MSCs), can be purified and culture-expanded from bone marrow, and are capable of forming bone when implanted ectopically in an appropriate carrier. To test the ability of MSCs to heal a critical-sized segmental defect, syngeneic culture-expanded MSCs were loaded onto a porous cylinder of hydroxyapatite/tricalcium phosphate (HA/TCP) and implanted in an 8-mm segmental defect in the femora of adult rats. For comparison, other defects received either marrow-loaded or cell-free HA/TCP cylinders, or no implant. The healing response was evaluated at 4 and 8 weeks by radiography, histology, and quantitative histomorphometry. Defects that received no implant, cell-free HA/TCP cylinders, or cylinders loaded with fresh marrow failed to heal by 8 weeks. In contrast, defects that received MSC-loaded cylinders showed significantly more bone formation at 4 weeks, and were completely healed by 8 weeks with excellent union of the host-implant interfaces. Histomorphometry demonstrates that bone fill in MSC-loaded implants (43%) is greater (p < 0.05) than that obtained with marrow-loaded (19%) or cell-free implants (10%).